SCHEMBL4292184

SCHEMBL4292184

Nc1cccc(Nc2cc(Oc3ccc4[nH]ccc4c3)ccn2)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 1/20 0.44
SCN5A Q14524 1/20 0.44
SCN9A Q15858 1/20 0.44
EGFR P00533 3/20 0.42
SYK P43405 1/20 0.41
CDK5 Q00535 2/20 0.41
JAK2 O60674 1/20 0.40
ABL1 P00519 2/20 0.40
BCR P11274 2/20 0.40
FGFR2 P21802 1/20 0.40
FLT3 P36888 1/20 0.40
TGFBR1 P36897 3/20 0.38
ROCK1 Q13464 1/20 0.38
KDR P35968 1/20 0.38
FLT1 P17948 1/20 0.37
SRC P12931 1/20 0.37
MEN1 O00255 1/20 0.36
NPC1 O15118 1/20 0.36
RAB9A P51151 1/20 0.36
KMT2A Q03164 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4288855 0.83 EGFR (0.42) SCN9AEGFRSYKCDK5JAK2
SCHEMBL4288245 0.83 CDK5 (0.49) EGFRSYKCDK5JAK2ABL1
SCHEMBL4279207 0.78 ABL1 (0.45) EGFRSYKJAK2ABL1BCR
SCHEMBL1893644 0.78 KDR (0.46) SCN9ASYKJAK2KDR
SCHEMBL28942653 0.71 EGFR (0.54) EGFRCDK5JAK2FLT3TGFBR1
SCHEMBL2502849 0.70 KDR (0.44) SYKKDRMEN1KMT2A
SCHEMBL14465628 0.70 AHR (0.46) SYKCDK5JAK2KDRCDK5R1
SCHEMBL4283784 0.70 KDR (0.49) SYKFLT3KDRFLT1
SCHEMBL4290886 0.70 KDR (0.49) EGFRSYKFLT3KDRFLT1
SCHEMBL4279286 0.70 KDR (0.49) SCN5ASCN9ASYKABL1BCR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090149467-A1 Tyrosine Kinase Inhibitors MERCK & CO., INC. (US) 2009-06-11 US claimed
EP-1934200-A1 TYROSINE KINASE INHIBITORS Merck & Co., Inc. (US) 2008-06-25 EP claimed
WO-2007035309-A1 TYROSINE KINASE INHIBITORS MERCK & CO., INC. (US) 2007-03-29 WO claimed
US-20090149467-A1 Tyrosine Kinase Inhibitors MERCK & CO., INC. (US) 2009-06-11 US disclosed
US-20090149467-A1 Tyrosine Kinase Inhibitors MERCK & CO., INC. (US) 2009-06-11 US disclosed
US-20090149467-A1 Tyrosine Kinase Inhibitors MERCK & CO., INC. (US) 2009-06-11 US disclosed
EP-1934200-A1 TYROSINE KINASE INHIBITORS Merck & Co., Inc. (US) 2008-06-25 EP disclosed
WO-2007035309-A1 TYROSINE KINASE INHIBITORS MERCK & CO., INC. (US) 2007-03-29 WO disclosed
WO-2007035309-A1 TYROSINE KINASE INHIBITORS MERCK & CO., INC. (US) 2007-03-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090149467-A1 Tyrosine Kinase Inhibitors ABL1, MET, ERBB2 KCNH2 4503/4885SCN5A 4330/4885SCN9A 4816/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.